<DOC>
	<DOCNO>NCT00304980</DOCNO>
	<brief_summary>The purpose study determine safety efficacy sulfadoxine-pyrimethamine ( SP ) versus artemether-lumefantrine ( Coartem ) administer HIV+ HIV- patient uncomplicated P. falciparum malaria . Patients randomise one 2 treatment follow ( day 14 actively ) 45 day .</brief_summary>
	<brief_title>Comparative Evaluation Safety Efficacy 2 Antimalarials Depending HIV Status</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<mesh_term>Fanasil , pyrimethamine drug combination</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>Man nonpregnant woman age 15 50 . P.falciparum monoinfection least 1,000 parasites/µl . Body temperature ≥ 37.5°C moment enrolment history fever precede 48 hr . Consent patient obtain . Pregnancy . Severe P. falciparum malaria . Documented intake SP Coartem two week less prior recruitment . Other cause ( ) fever . Evidence underlie chronic disease ( cardiac , renal , hepatic , malnutrition ) . History allergy study drug , know allergy Sulphur drug cotrimoxazol .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>